Literature DB >> 8518099

Intraperitoneal production of erythropoietin with continuous ambulatory peritoneal dialysis.

M Chandra1, G Clemons, I Sahdev, M McVicar, P Bluestone.   

Abstract

Higher hematocrit and serum erythropoietin (EPO) levels have previously been shown in end-stage renal disease patients treated with continuous ambulatory peritoneal dialysis (CAPD) compared with hemodialysis. We investigated whether EPO was produced intraperitoneally in CAPD patients. EPO concentration was 3.5 +/- 0.3 mU/ml by radioimmunoassay in 26 samples of peritoneal dialysis effluent obtained from 15 CAPD patients. EPO was not detectable in the fresh unused dialysate. No correlation was observed between EPO levels in the serum and dialysis effluent. Peritoneal macrophages were isolated from the dialysis effluent of 9 CAPD patients after an overnight dwell. The culture supernatant obtained after 24 h of in vitro culture of a million cells yielded EPO of 3.5 +/- 0.3 mU/ml. Our study demonstrated that peritoneal macrophages from CAPD patients produce EPO on in vitro stimulation, and EPO is present in the dialysis effluent of CAPD patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8518099     DOI: 10.1007/BF00853222

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  18 in total

1.  Peritoneal dialysis fluid induces change of mononuclear phagocyte proportions.

Authors:  H J Bos; F Meyer; J C de Veld; R H Beelen
Journal:  Kidney Int       Date:  1989-07       Impact factor: 10.612

Review 2.  Peritoneal transport physiology: insights from basic research.

Authors:  M F Flessner
Journal:  J Am Soc Nephrol       Date:  1991-08       Impact factor: 10.121

3.  Activation of immunocompetent cells in the peritoneum of patients treated with CAPD.

Authors:  S J Davies; J Suassuna; C S Ogg; J S Cameron
Journal:  Kidney Int       Date:  1989-10       Impact factor: 10.612

4.  Release of erythropoietin from macrophages mediated by phagocytosis of crystalline silica.

Authors:  I N Rich; B Kubanek
Journal:  J Reticuloendothel Soc       Date:  1982-01

5.  Analysis of peritoneal macrophages in continuous ambulatory peritoneal dialysis patients.

Authors:  C S Goldstein; J S Bomalaski; R B Zurier; E G Neilson; S D Douglas
Journal:  Kidney Int       Date:  1984-11       Impact factor: 10.612

6.  Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.

Authors:  I C Macdougall; D E Roberts; P Neubert; A D Dharmasena; G A Coles; J D Williams
Journal:  Lancet       Date:  1989-02-25       Impact factor: 79.321

7.  Role of erythropoietin in the reversal of anemia of renal failure with continuous ambulatory peritoneal dialysis.

Authors:  M Chandra; M McVicar; G Clemons; R T Mossey; B M Wilkes
Journal:  Nephron       Date:  1987       Impact factor: 2.847

8.  Erythropoietin and uremic toxicity during continuous ambulatory peritoneal dialysis.

Authors:  T E Wideröe; T Sanengen; S Halvorsen
Journal:  Kidney Int Suppl       Date:  1983-12       Impact factor: 10.545

9.  Normalization of hematocrit in patients with end-stage renal disease on continuous ambulatory peritoneal dialysis: the role of erythropoietin.

Authors:  A R Zappacosta; J Caro; A Erslev
Journal:  Am J Med       Date:  1982-01       Impact factor: 4.965

10.  Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous, and intraperitoneal routes in continuous ambulatory peritoneal dialysis (CAPD) patients.

Authors:  J R Boelaert; M L Schurgers; E G Matthys; F M Belpaire; R F Daneels; M J De Cre; M G Bogaert
Journal:  Perit Dial Int       Date:  1989       Impact factor: 1.756

View more
  1 in total

1.  Pharmacokinetics of recombinant human erythropoietin in children with chronic renal failure.

Authors:  N Cakar; M Ekim; N Tümer; F Yalçinkaya; N Akar; H O Onaran
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.